Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...

Sanofi perd 250 M$ dans l’échec de son vaccin contre E. coli en phase III Sanofi va devoir revoir ses résultats du dernier trimestre 2024. Le laboratoire fait ainsi face à une charge de ...

It is a good idea to leave them unpruned over winter: they provide food and shelter for wildlife and can look attractive even in decay, particularly when sprinkled with frost on cold mornings ...

Le jeune homme en effet n’a que… 19 ans. Quand des personnes se voient diagnostiquer un Alzheimer précoce, elles ont une cinquantaine d’années en général. Il est possible de l’avoir ...

Face à la crise industrielle qui affaiblit l’Allemagne pointe la nostalgie de l’après-guerre, quand « tout le monde ... désormais partie du géant Sanofi-Aventis. Comme son père et ...

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

(Reuters) – Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the ...